Tags

Type your tag names separated by a space and hit enter

Adverse event reports following yellow fever vaccination.
Vaccine. 2008 Nov 11; 26(48):6077-82.V

Abstract

Yellow fever (YF) vaccine has been used for prevention of YF since 1937 with over 500 million doses administered. However, rare reports of severe adverse events following vaccination have raised concerns about the vaccine's safety. We reviewed reports of adverse events following YF vaccination reported to the U.S. Vaccine Adverse Event Reporting System (VAERS) from 2000 to 2006. We used estimates of age and sex distribution of administered doses obtained from a 2006 survey of authorized vaccine providers to calculate age- and sex-specific reporting rates of all serious adverse events (SAE), anaphylaxis, YF vaccine-associated neurotropic disease, and YF vaccine-associated viscerotropic disease. Reporting rates of SAEs were substantially higher in males and in persons aged > or =60 years. These findings reinforce the generally acceptable safety profile of YF vaccine, but highlight the importance of physician and traveler education regarding the risks and benefits of YF vaccination, particularly for travelers > or =60 years of age. Vaccination should be limited to persons traveling to areas where the risk of YF is expected to exceed the risk of serious adverse events after vaccination, or if not medically contraindicated, where national regulations require proof of vaccination to prevent introduction of YF.

Authors+Show Affiliations

Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases, Centers for Disease Control and Prevention, Fort Collins, CO, USA. nplindsey@cdc.govNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

18809449

Citation

Lindsey, Nicole P., et al. "Adverse Event Reports Following Yellow Fever Vaccination." Vaccine, vol. 26, no. 48, 2008, pp. 6077-82.
Lindsey NP, Schroeder BA, Miller ER, et al. Adverse event reports following yellow fever vaccination. Vaccine. 2008;26(48):6077-82.
Lindsey, N. P., Schroeder, B. A., Miller, E. R., Braun, M. M., Hinckley, A. F., Marano, N., Slade, B. A., Barnett, E. D., Brunette, G. W., Horan, K., Staples, J. E., Kozarsky, P. E., & Hayes, E. B. (2008). Adverse event reports following yellow fever vaccination. Vaccine, 26(48), 6077-82. https://doi.org/10.1016/j.vaccine.2008.09.009
Lindsey NP, et al. Adverse Event Reports Following Yellow Fever Vaccination. Vaccine. 2008 Nov 11;26(48):6077-82. PubMed PMID: 18809449.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Adverse event reports following yellow fever vaccination. AU - Lindsey,Nicole P, AU - Schroeder,Betsy A, AU - Miller,Elaine R, AU - Braun,M Miles, AU - Hinckley,Alison F, AU - Marano,Nina, AU - Slade,Barbara A, AU - Barnett,Elizabeth D, AU - Brunette,Gary W, AU - Horan,Katherine, AU - Staples,J Erin, AU - Kozarsky,Phyllis E, AU - Hayes,Edward B, Y1 - 2008/09/20/ PY - 2008/07/02/received PY - 2008/08/14/revised PY - 2008/09/02/accepted PY - 2008/9/24/pubmed PY - 2009/1/17/medline PY - 2008/9/24/entrez SP - 6077 EP - 82 JF - Vaccine JO - Vaccine VL - 26 IS - 48 N2 - Yellow fever (YF) vaccine has been used for prevention of YF since 1937 with over 500 million doses administered. However, rare reports of severe adverse events following vaccination have raised concerns about the vaccine's safety. We reviewed reports of adverse events following YF vaccination reported to the U.S. Vaccine Adverse Event Reporting System (VAERS) from 2000 to 2006. We used estimates of age and sex distribution of administered doses obtained from a 2006 survey of authorized vaccine providers to calculate age- and sex-specific reporting rates of all serious adverse events (SAE), anaphylaxis, YF vaccine-associated neurotropic disease, and YF vaccine-associated viscerotropic disease. Reporting rates of SAEs were substantially higher in males and in persons aged > or =60 years. These findings reinforce the generally acceptable safety profile of YF vaccine, but highlight the importance of physician and traveler education regarding the risks and benefits of YF vaccination, particularly for travelers > or =60 years of age. Vaccination should be limited to persons traveling to areas where the risk of YF is expected to exceed the risk of serious adverse events after vaccination, or if not medically contraindicated, where national regulations require proof of vaccination to prevent introduction of YF. SN - 0264-410X UR - https://www.unboundmedicine.com/medline/citation/18809449/Adverse_event_reports_following_yellow_fever_vaccination_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(08)01230-9 DB - PRIME DP - Unbound Medicine ER -